Nanobiotix

NANOFR0011341205

Nanobiotix is a biotechnology company that uses nanomedicine to develop new radiotherapy techniques for cancer patients. The company is headquartered in Paris, with additional corporate offices in New York and Massachusetts.

Filings

142 filings

All Inside information63 Voting rights and capital32 Threshold crossing29 Quarterly financial information5 Earnings release4 Annual financial report4 Universal registration document2 Tender offer2

01/10/2025
NANOBIOTIX Announces First Data From Phase 1 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Esophageal Cancer
Inside informationFR
30/09/2025
RAPPORT FINANCIER SEMESTRIEL
Half-year financial reportFrench
30/09/2025
NANOBIOTIX Provides Business Update and Reports Half Year 2025 Financial Results
Earnings releaseFR
30/09/2025
NANOBIOTIX Announces Updated Phase 1 Results Continuing to Support JNJ-1900 (NBTXR3) Plus Anti-PD-1 as a Potential New 1L or 2L+ Option in Anti-PD-1 Naïve or Resistant R/M-HNSCC
Inside information
19/09/2025
Franchissements de seuils
Threshold crossingFrench
17/09/2025
NANOBIOTIX Announces New Results From a Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Combination With Immune Checkpoint Inhibitors as a 2L+ Therapy for Patients With Primary Cutaneous Melanoma Resistant to Anti-PD-1
Inside informationFR
12/09/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
09/09/2025
Franchissement de seuils
Threshold crossingFrench
08/09/2025
Franchissement de seuils
Threshold crossingFrench
02/09/2025
Nanobiotix to Participate in the H.C. Wainwright 27th Annual Global Investment Conference
Inside informationFR
27/08/2025
Voting Rights and Shares Capital of the Company
Voting rights and capital
11/08/2025
Franchissements de seuils
Threshold crossingFrench
11/08/2025
Franchissements de seuils
Threshold crossingFrench
11/07/2025
Franchissement de seuils
Threshold crossingFrench
11/07/2025
Franchissement de seuils
Threshold crossingFrench
07/07/2025
NANOBIOTIX Announces Regulatory Harmonization and New Composition of Matter Patent Filed for JNJ-1900 (NBTXR3)
Inside informationFR
01/07/2025
Franchissement de seuils
Threshold crossingFrench
24/06/2025
Franchissement de seuils
Threshold crossingFrench
20/06/2025
Franchissement de seuils
Threshold crossingFrench
20/06/2025
Franchissement de seuils
Threshold crossingFrench
10/06/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
28/05/2025
NANOBIOTIX to Participate in the Jefferies Global Healthcare Investor Conference
Inside informationFR
21/05/2025
Nanobiotix Provides First Quarter 2025 Operational and Financial Update
Quarterly financial informationFR
14/05/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
12/05/2025
Nanobiotix to Participate in the H.C. Wainwright 3rd Annual BioConnect Investor Conference at NASDAQ
Inside informationFR
05/05/2025
Nanobiotix Announces Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer
Inside informationFR
30/04/2025
Nanobiotix Announces Presentation of Full Results From Completed Phase 1 Study Evaluating JNJ-1900 (NBTXR3) in Pancreatic Cancer Followed by a Conference Call
Inside informationFR
14/04/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
02/04/2025
Document d'Enregistrement Universel
Universal registration documentFrenchZIP
02/04/2025
NANOBIOTIX Provides Business Update and Reports Full Year 2024 Financial Results
Annual financial reportFR
31/03/2025
NANOBIOTIX to Announce Fourth Quarter and Full Year 2024 Operational and Financial Update on April 2, 2025
Inside information
31/03/2025
NANOBIOTIX publiera ses résultats financiers et opérationnels de l’exercice 2024 le 2 avril 2025
Earnings releaseFrench
27/03/2025
Nanobiotix Announces First Data From the Completed Dose Escalation Part of a Phase 1 Study Evaluating NBTXR3 (JNJ-1900) as a 2L+ Therapy for Patients With Locally Advanced NSCLC
Inside informationFR
20/03/2025
NANOBIOTIX Announces Presentation of Data From Two Phase 1 Studies Evaluating JNJ-1900 (NBTXR3) at the European Lung Cancer Conference
Inside informationFR
17/03/2025
NANOBIOTIX Strengthens Financial Position Through Amendment of Global Licensing Agreement for JNJ-1900 (NBTXR3) and Extends Cash Visibility to Mid-2026
Inside informationFR
13/03/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
12/02/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR
29/01/2025
Nanobiotix to Participate in Multiple Investor Conferences in February and March 2025
Inside information
21/01/2025
NANOBIOTIX Announces First Patient Dosed in a New Randomized Phase 2 Study Evaluating JNJ-1900 (NBTXR3) for Patients With Stage 3 Unresectable Non-Small Cell Lung Cancer
Inside informationFR
09/01/2025
Voting Rights and Shares Capital of the Company
Voting rights and capitalFR

About

ISIN: FR0011341205
Ticker: NANO
LEI: 969500667RSYIH8YL895
Founded: 2003
Country of registration: FR
Last filing: 30/07/2026, 22:15

Wikipedia

Description from Wikidata, CC0 licence.

Filing history

Filings per month

Sept 23May 24Jan 25Sept 25Aug 26

Document types

Across the whole archive